- Home
- DBX vs VRNA Comparison
DBX vs VRNA Comparison
Compare DBX & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBX
- VRNA
- Stock Information
- Founded
- DBX 2007
- VRNA 2005
- Country
- DBX United States
- VRNA United Kingdom
- Employees
- DBX N/A
- VRNA N/A
- Industry
- DBX Computer Software: Prepackaged Software
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- DBX Technology
- VRNA Health Care
- Exchange
- DBX Nasdaq
- VRNA Nasdaq
- Market Cap
- DBX 8.3B
- VRNA 8.3B
- IPO Year
- DBX 2018
- VRNA 2017
- Fundamental
- Price
- DBX $32.09
- VRNA $106.33
- Analyst Decision
- DBX Hold
- VRNA Buy
- Analyst Count
- DBX 5
- VRNA 11
- Target Price
- DBX $30.50
- VRNA $114.10
- AVG Volume (30 Days)
- DBX 2.9M
- VRNA 1.3M
- Earning Date
- DBX 11-06-2025
- VRNA 11-03-2025
- Dividend Yield
- DBX N/A
- VRNA N/A
- EPS Growth
- DBX N/A
- VRNA N/A
- EPS
- DBX 1.57
- VRNA N/A
- Revenue
- DBX $2,532,800,000.00
- VRNA $221,673,000.00
- Revenue This Year
- DBX N/A
- VRNA $896.59
- Revenue Next Year
- DBX N/A
- VRNA $77.56
- P/E Ratio
- DBX $20.40
- VRNA N/A
- Revenue Growth
- DBX N/A
- VRNA N/A
- 52 Week Low
- DBX $24.25
- VRNA $27.54
- 52 Week High
- DBX $33.33
- VRNA $106.45
- Technical
- Relative Strength Index (RSI)
- DBX 74.49
- VRNA 68.40
- Support Level
- DBX $30.51
- VRNA $106.15
- Resistance Level
- DBX $31.29
- VRNA $106.42
- Average True Range (ATR)
- DBX 0.63
- VRNA 0.19
- MACD
- DBX 0.24
- VRNA -0.17
- Stochastic Oscillator
- DBX 92.49
- VRNA 76.32
About DBX Dropbox Inc.
Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.